BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 34910788)

  • 1. Bioinformatics analysis for the role of CALR in human cancers.
    Li Y; Liu X; Chen H; Xie P; Ma R; He J; Zhang H
    PLoS One; 2021; 16(12):e0261254. PubMed ID: 34910788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Calreticulin as a prognostic biomarker and correlated with immune infiltrate in kidney renal clear cell carcinoma.
    Sun M; Qi S; Wu M; Xia W; Xiong H
    Front Genet; 2022; 13():909556. PubMed ID: 36338983
    [No Abstract]   [Full Text] [Related]  

  • 3. Integrated bioinformatic analysis of HNF1A in human cancers.
    Zhang E; Huang X; He J
    J Int Med Res; 2021 Mar; 49(3):300060521997326. PubMed ID: 33752475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calreticulin increases growth and progression of natural killer/T-cell lymphoma.
    Zheng Y; Li C; Xin P; Peng Q; Zhang W; Liu S; Zhu X
    Aging (Albany NY); 2020 Nov; 12(23):23822-23835. PubMed ID: 33221760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive Transcriptomic Analysis Reveals the Role of the Immune Checkpoint HLA-G Molecule in Cancers.
    Xu HH; Gan J; Xu DP; Li L; Yan WH
    Front Immunol; 2021; 12():614773. PubMed ID: 34276642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive Analysis of Fibroblast Growth Factor Receptor (FGFR) Family Genes in Breast Cancer by Integrating Online Databases and Bioinformatics.
    Zhou Z; Wu B; Tang X; Ke R; Zou Q
    Med Sci Monit; 2020 May; 26():e923517. PubMed ID: 32381997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential expression and molecular interactions of chromosome region maintenance 1 and calreticulin exportins in breast cancer cells.
    Cruz-Ramos E; Sandoval-Hernández A; Tecalco-Cruz AC
    J Steroid Biochem Mol Biol; 2019 Jan; 185():7-16. PubMed ID: 29981820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation of expression levels of ANXA2, PGAM1, and CALR with glioma grade and prognosis.
    Gao H; Yu B; Yan Y; Shen J; Zhao S; Zhu J; Qin W; Gao Y
    J Neurosurg; 2013 Apr; 118(4):846-53. PubMed ID: 23082878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunosuppression by Mutated Calreticulin Released from Malignant Cells.
    Liu P; Zhao L; Loos F; Marty C; Xie W; Martins I; Lachkar S; Qu B; Waeckel-Énée E; Plo I; Vainchenker W; Perez F; Rodriguez D; López-Otin C; van Endert P; Zitvogel L; Kepp O; Kroemer G
    Mol Cell; 2020 Feb; 77(4):748-760.e9. PubMed ID: 31785928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Calreticulin and cancer.
    Fucikova J; Spisek R; Kroemer G; Galluzzi L
    Cell Res; 2021 Jan; 31(1):5-16. PubMed ID: 32733014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calreticulin Expression Controls Cellular Redox, Stemness, and Radiosensitivity to Function as a Novel Adjuvant for Radiotherapy in Neuroblastoma.
    Chen CJ; Hu YC; Chien Y; Huang WC; Wu CS; Tsai CY; Lin YH; Lee MS; Chien CS; Yang YP; Lee MC; Tseng CC; Chi HC
    Oxid Med Cell Longev; 2023; 2023():8753309. PubMed ID: 36644580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conformation sensitive gel electrophoresis for the detection of calreticulin mutations in BCR-ABL1-negative myeloproliferative neoplasms.
    Zakaria NA; Rosle NA; Siti Asmaa MJ; Aziee S; Haiyuni MY; Samat NA; Husin A; Hassan R; Ramli M; Mohamed Yusoff S; Ibrahim IK; Al-Jamal HAN; Johan MF
    Int J Lab Hematol; 2021 Dec; 43(6):1451-1457. PubMed ID: 34125992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surface-exposed and soluble calreticulin: conflicting biomarkers for cancer prognosis.
    Kepp O; Liu P; Zhao L; Plo I; Kroemer G
    Oncoimmunology; 2020 Jul; 9(1):1792037. PubMed ID: 32923154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Calreticulin mutation specific CAL2 immunohistochemistry accurately identifies rare calreticulin mutations in myeloproliferative neoplasms.
    Mózes R; Gángó A; Sulák A; Vida L; Reiniger L; Timár B; Krenács T; Alizadeh H; Masszi T; Gaál-Weisinger J; Demeter J; Csomor J; Matolcsy A; Kajtár B; Bödör C
    Pathology; 2019 Apr; 51(3):301-307. PubMed ID: 30606612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Calreticulin is crucial for calcium homeostasis mediated adaptation and survival of thick ascending limb of Henle's loop cells under osmotic stress.
    Bibi A; Agarwal NK; Dihazi GH; Eltoweissy M; Van Nguyen P; Mueller GA; Dihazi H
    Int J Biochem Cell Biol; 2011 Aug; 43(8):1187-97. PubMed ID: 21554974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Driver mutations and prognosis in primary myelofibrosis: Mayo-Careggi MPN alliance study of 1,095 patients.
    Tefferi A; Nicolosi M; Mudireddy M; Szuber N; Finke CM; Lasho TL; Hanson CA; Ketterling RP; Pardanani A; Gangat N; Mannarelli C; Fanelli T; Guglielmelli P; Vannucchi AM
    Am J Hematol; 2018 Mar; 93(3):348-355. PubMed ID: 29164670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutant specific anti calreticulin antibody (CAL2) immunohistochemistry as a screening test for calreticulin (CALR) mutation testing.
    Rahman K; Chandra D; Singh MK; Gupta R; Sharma A; Paul P; Kumar S; Sharma S; Nityanand S
    Int J Lab Hematol; 2020 Oct; 42(5):604-611. PubMed ID: 32463176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pancancer Analyses Reveal Genomics and Clinical Characteristics of the SETDB1 in Human Tumors.
    Lin X; Xiao M; Chen Z; Ding C; Zhang T; Li Q
    J Oncol; 2022; 2022():6115878. PubMed ID: 35656340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficient induction of anti-tumor immune response in esophageal squamous cell carcinoma via dendritic cells expressing MAGE-A3 and CALR antigens.
    Liu X; Song N; Liu Y; Liu Y; Li J; Ding J; Tong Z
    Cell Immunol; 2015 Jun; 295(2):77-82. PubMed ID: 25863743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rare type 1-like and type 2-like calreticulin mutants induce similar myeloproliferative neoplasms as prevalent type 1 and 2 mutants in mice.
    Toppaldoddi KR; da Costa Cacemiro M; Bluteau O; Panneau-Schmaltz B; Pioch A; Muller D; Villeval JL; Raslova H; Constantinescu SN; Plo I; Vainchenker W; Marty C
    Oncogene; 2019 Mar; 38(10):1651-1660. PubMed ID: 30846848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.